{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:18:12Z","timestamp":1792513092371,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004784","name":"SAS Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009459","name":"Society for Anthropological Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clgc.2024.102174","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T04:20:17Z","timestamp":1721881217000},"page":"102174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3216-7713","authenticated-orcid":false,"given":"Vinicius Carrera","family":"Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Sabino Marques","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4288-9018","authenticated-orcid":false,"given":"Fernando Cotait","family":"Maluf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Werutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa de Carvalho","family":"Fabr\u00edcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie","family":"Gidekel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Natalia","family":"Gandur-Quiroga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Roberto Pereira","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0575-5635","authenticated-orcid":false,"given":"Murilo","family":"Luz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul","family":"Campos-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Augusto Rinck","family":"Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo Assed","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Sade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine Martins","family":"da Trindade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto Cesar de Andrade","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni de Carvalho","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan Omar Barillas","family":"Ru\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breno Dauster","family":"Pereira e Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Nunes Galv\u00e3o","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan Javier","family":"Cutuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Fernando Garc\u00eda","family":"Aceituno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Inman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Caitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Herchenhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Ardila-Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6912-2995","authenticated-orcid":false,"given":"Rafaela Gomes","family":"de Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"G\u00f6ssling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4980-6729","authenticated-orcid":false,"given":"Andrey","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Poisl","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10236","key":"10.1016\/j.clgc.2024.102174_bib0001","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2024.102174_bib0002","unstructured":"Cancer CSFB. Cancer stat facts: bladder cancer 202. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. Accessed 20 Jan, 2024."},{"issue":"4","key":"10.1016\/j.clgc.2024.102174_bib0003","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3322\/caac.20077","article-title":"Bladder cancer in 2010: how far have we come?","volume":"60","author":"Jacobs","year":"2010","journal-title":"Cancer J Clin"},{"issue":"2","key":"10.1016\/j.clgc.2024.102174_bib0004","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/annonc\/mdx692","article-title":"Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a retrospective international study of invasive\/advanced cancer of the urothelium (RISC)","volume":"29","author":"Bamias","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102174_bib0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/BJ20101603","article-title":"Fibroblast growth factors and their receptors in cancer","volume":"437","author":"Wesche","year":"2011","journal-title":"Biochem J"},{"issue":"5","key":"10.1016\/j.clgc.2024.102174_bib0006","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signaling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2024.102174_bib0007","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2022.40.6_suppl.537","article-title":"Prognostic impact of fibroblast growth factor receptor (FGFR) genomic alterations and outcomes in patients with metastatic urothelial","volume":"40","author":"Sevillano","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.clgc.2024.102174_bib0008","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.3390\/jcm11154483","article-title":"Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients","volume":"11","author":"Sevillano Fern\u00e1ndez","year":"2022","journal-title":"J Clin Med [Internet]"},{"issue":"6","key":"10.1016\/j.clgc.2024.102174_bib0009","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.eururo.2020.07.018","article-title":"Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma","volume":"78","author":"Teo","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102174_bib0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.urology.2021.05.055","article-title":"Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer undergoing checkpoint inhibitor therapy","volume":"157","author":"Tully","year":"2021","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.clgc.2024.102174_bib0011","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.eururo.2019.06.025","article-title":"Fibroblast growth factor receptor 3 alterations and response to PD-1\/PD-L1 blockade in patients with metastatic urothelial cancer","volume":"76","author":"Wang","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102174_bib0012","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"New Eng J Med"},{"key":"10.1016\/j.clgc.2024.102174_bib0013","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fonc.2020.00167","article-title":"Current treatment and outcomes benchmark for locally advanced or metastatic urothelial cancer from a large UK-based single centre","volume":"10","author":"Cheeseman","year":"2020","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102174_bib0014","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.3390\/curroncol28050325","article-title":"Survival outcomes associated with first and second-line palliative systemic therapies in patients with metastatic bladder cancer","volume":"28","author":"Beigi","year":"2021","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102174_bib0015","doi-asserted-by":"crossref","first-page":"15822","DOI":"10.1038\/s41598-020-72820-y","article-title":"Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands","volume":"10","author":"Reesink","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2024.102174_bib0016","first-page":"2943","article-title":"Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real\u2011world data of advanced urothelial carcinoma","volume":"19","author":"Furubayashi","year":"2020","journal-title":"Oncol Letters"},{"issue":"6","key":"10.1016\/j.clgc.2024.102174_bib0017","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1016\/j.clgc.2018.07.025","article-title":"Treatment patterns and outcomes in stage IV bladder cancer in a community oncology setting: 2008-2015","volume":"16","author":"Fisher","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2024.102174_bib0018","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/JU.0000000000001002","article-title":"Upper tract urothelial carcinoma has a luminal-papillary t-cell depleted contexture and activated FGFR3 signaling","volume":"203","author":"Re","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2024.102174_bib0019","unstructured":"Database S. Stage distribution of SEER incidence cases, 2010-2019. Avaliable from: https:\/\/seer.cancer.gov\/data. Accessed 20 Jan, 2024."},{"issue":"1","key":"10.1016\/j.clgc.2024.102174_bib0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.urology.2007.03.033","article-title":"Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection","volume":"70","author":"Wasco","year":"2007","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.clgc.2024.102174_bib0021","doi-asserted-by":"crossref","DOI":"10.1186\/s42047-020-00066-z","article-title":"Divergent differentiation and variant morphology in invasive urothelial carcinomas \u2013 association with muscle-invasive disease","volume":"3","author":"Santana","year":"2020","journal-title":"Surg Experiment Pathol"},{"issue":"6 Suppl 4","key":"10.1016\/j.clgc.2024.102174_bib0022","first-page":"S193","article-title":"Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer","volume":"3","author":"Chalasani","year":"2009","journal-title":"Can Urol Assoc J"},{"issue":"6","key":"10.1016\/j.clgc.2024.102174_bib0023","doi-asserted-by":"crossref","first-page":"877","DOI":"10.21037\/tau-22-43","article-title":"Overview of histologic variants of urothelial carcinoma: current trends and narrative review on treatment outcomes","volume":"11","author":"Ogbue","year":"2022","journal-title":"Transl Androl Urol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102174_bib0024","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/JU.0000000000001305","article-title":"A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy","volume":"204","author":"Mori","year":"2020","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.clgc.2024.102174_bib0025","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.21037\/tcr-20-2169","article-title":"Variant histology in bladder cancer: diagnostic and clinical implications","volume":"9","author":"Black","year":"2020","journal-title":"Transl Cancer Res"},{"issue":"2","key":"10.1016\/j.clgc.2024.102174_bib0026","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/modpathol.2013.135","article-title":"Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy","volume":"27","author":"Ross","year":"2014","journal-title":"Modern Pathol"},{"issue":"11","key":"10.1016\/j.clgc.2024.102174_bib0027","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102174_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.11.014","article-title":"Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States","volume":"40","author":"Geynisman","year":"2022","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102174_bib0029","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1634\/theoncologist.2018-0084","article-title":"FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy","volume":"24","author":"Suzman","year":"2019","journal-title":"Oncologist"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T06:58:29Z","timestamp":1738565909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1558767324001459"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102174","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102174"}}